KEY INFORMATION DOCUMENT



PURPOSE: This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

PRODUCT

Kieger Sustainable Healthcare Fund - Class A GBP (Acc)


a Sub-Fund of Kieger UCITS Fund

ISIN: LU2697580079

Contact Details: 33, ru Call (+ Website: www.f Competent authority: Comm this K Finand Date of production: 16/02/ WHAT IS THIS PROD Type : This pro Term : This pro Objectives : The Sut worldwic you may The Sut America	DUCT? oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. bb-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Call (- Website: www.1 Competent authority: Comm this K Finan Date of production: 16/02 WHAT IS THIS PROD Type : This pro Term : This pro Objectives : The Sub worldwic you may The Sub	(+352) 27 111 1 for more information fundrock.com mission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundRock Management Company S.A. in relation to Key Information Document. Kieger UCITS Fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur ncier (CSSF). 2/2024 DUCT? oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. Ib-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. Ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Website: www.f Competent authority: Comn this K Finan Date of production: 16/02 WHAT IS THIS PROD Type : This pro Objectives : The Sut worldwic you may The Sut America The Sut	.fundrock.com mission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundRock Management Company S.A. in relation to Key Information Document. Kieger UCITS Fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur ncier (CSSF). 2/2024 DUCT? Doduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. Ib-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and by not get back the original amount you invested. Ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Competent authority: Comm this K Finand Date of production: 16/02/ WHAT IS THIS PROD Type : This pro Term : This pro Objectives : The Sub worldwic you may The Sub America The Sub	mission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundRock Management Company S.A. in relation to Key Information Document. Kieger UCITS Fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur ncier (CSSF). 2/2024 DUCT? oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. Ib-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and by not get back the original amount you invested. Ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
this K Finan Date of production: 16/02/ WHAT IS THIS PROD Type : This pro Term : This pro Objectives : The Sub worldwic you may The Sub America The Sub	Key Information Document. Kieger UCITS Fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur Incier (CSSF). 2/2024 DUCT? oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. Ib-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and by not get back the original amount you invested. Ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
WHAT IS THIS PRODUCT Type : This pro Term : This pro Objectives : The Sub worldwic you may The Sub America The Sub	DUCT? oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. b-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. b-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Type : This pro Term : This pro Objectives : The Sub worldwic you may The Sub America The Sub	oduct is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS). oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. b-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. b-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Term : This pro Objectives : The Sub worldwic you may The Sub America The Sub	oduct has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances. b-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. b-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
Objectives : The Sub worldwic you may The Sub America The Sub	b-Fund aims to achieve long term capital growth by principally investing to invest in equities of healthcare and healthcare related issuers ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
worldwic you may The Sut America The Sut	ide (including Emerging Markets). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and y not get back the original amount you invested. ib-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as depositary receipts,
The Sut collectiv principal More tha For hed, OTC (O On a ter Benchm performa The Sub product and on t Distribu the valu The Sub	an Depositary Receipts, Global Depositary Receipts, etc.) of issuer worldwide, including real estate investment trust ("REITs"). ib-Fund is not constrained as to currency of denomination (which must be freely convertible), market capitalization, industrial sector or phy. ib-Fund may invest up to 10% of its net assets in Money Market Instruments and up to 10% in other UCITS or Other Undertakings for ve investment (UCIs) (whether or not they are exchange traded), provided that such UCITS or other collective investment funds which ally invest in the types of instruments mentioned above. han 50% of the asset value of each Sub-Fund will be invested on an ongoing basis in equity participations. dging and investment purposes, the Sub-Fund may use all types of financial derivative instruments traded on a Regulated Market and/or Diver the Counter). Imporary basis and for defensive purposes, the Sub-Fund may also hold up to 100% of its net assets in liquid assets. mark: The Sub-Fund is actively managed by reference to the MSCI World Health Care Net Index (the "Benchmark") for the purposes of hance measurement. There are no restrictions on the extent to which the Sub-Fund's holdings may deviate from the Benchmark. b-Fund meets the criteria in Article 9 of the Sustainable Finance Disclosure Regulation (Regulation EU/2019/2088) to qualify as a financial t that has sustainable investment as its objective. More information on this product's sustainability factors can be found in the Prospectus the following website: www.kieger.com. ution Policy: Your shares will be accumulating. Income from investments in the Sub-Fund will be re-invested and therefore rolled up into us of your shares. b-Fund launched on 01 September 2020. The Share Class launched on 04 October 2023 . rrency of the Fund is USD, the currency of this product is GBP.
investor : as Institu the med capital g and acc	restors should note that the sale and transfer of the "A" shares is restricted to persons that can provide sufficient evidence that they qualify tutional Investors and who satisfy the minimum investment threshold for the relevant Sub-Fund. An investor should be willing to invest for dium to long term (five years) to gain access to a portfolio managed in accordance with an investment objective and policy which targets growth and income from equities. Investors must be prepared to accept fluctuations in the value of capital including possible capital loss cept the risks of investing in equity markets. Investors should understand the risks involved, including the risk of losing all capital invested ust evaluate. The Company's objective and risks in terms of whether they are consistent with their own investment goals and risk ces.
	rn Trust Global Services SE

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?





Ö We have classified this product as 4 out of 7, which is a medium risk class. This

rates the potential losses from future performance at a medium level, and poor market conditions could impact our capacity to pay you.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Investors shall note that the product may be exposed to risks such as risk associated with investing in emerging markets, the value of equities and equity-related securities, currency risk, counterparty risk, active management, credit risk, derivatives Instruments, Risks associated with Depositary Receipts and Environmental, Social and Governance Risk (ESG). For further details of the Fund's risks please see the Prospectus.

This product does not include any protection from future market performance so you could lose some or all of your investment. If not able to pay you what is owed, you could lose your entire investment.

Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product/ suitable benchmark over the last 10 years. The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

Recommended holding period (RHP): 5 years Example Investment: 10,000 GBP					
Scenarios		If you exit after 1 year	If you exit after 5 years (RHP)		
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.				
Stress	What you might get back after costs	6,050 GBP	5,140 GBP		
	Average return each year	-39.46%	-12.46%		
Unfavourable	What you might get back after costs	9,310 GBP	9,970 GBP		
	Average return each year	-6.90%	-0.07%		
Moderate	What you might get back after costs	11,170 GBP	17,460 GBP		
	Average return each year	11.75%	11.79%		
Favourable	What you might get back after costs	13,540 GBP	19,620 GBP		
	Average return each year	35.44%	14.43%		

Unfavourable scenario: This type of scenario occurred for an investment/benchmark or proxy between November 2022 and December 2023

Moderate scenario: This type of scenario occurred for an investment/benchmark or proxy between February 2018 and February 2023

Favourable scenario: This type of scenario occurred for an investment/benchmark or proxy between July 2014 and July 2019

The figures shown include all the costs of the product itself but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

WHAT HAPPENS IF FUNDROCK MANAGEMENT COMPANY S.A. IS UNABLE TO PAY OUT ?

The Management Company is responsible for administration and management of the Fund, and does not typically hold assets of the Fund (assets that can be held by a depositary are, in line with applicable regulations, held with a depositary in its custody network). The Management Company, as the PRIIPs manufacturer has no obligation to pay out since the product design does not contemplate any such payment being made. However, investors may suffer loss if the Fund or the depositary is unable to pay out. There is no compensation or guarantee scheme in place which may offset, all or any, of this loss.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Cost over time

The tables below show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts are illustrations based on an example investment amount and different possible investment periods. We have assumed:

In the first year you would get back the amount that you invested (0% annual return).

• For the other holding periods we have assumed the product performs as shown in the moderate scenario.

•10,000 GBP is invested.

Example Investment: 10,000 GBP	lf you exit after 1 year	If you exit after 5 years (RHP)
Total costs	111 GBP	994 GBP
Annual cost impact(*)	1.11%	1.25%

*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 13.04% before costs and 11.79% after costs.

Composition of costs

One-off costs upon entry or exit			
Entry costs	We do not charge an entry fee for this product.	0 GBP	
Exit costs	We do not charge an entry fee for this product.	0 GBP	
Ongoing costs taken each year			
Management fees and other administrative or operating costs	0.99% of the value of your investment per year. This is an estimate based on actual costs over the last year.	100 GBP	
Transaction costs	0.11% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	11 GBP	
Incidental costs taken under specific conditions			
Performance fees and carried interest	There is no performance fee or carried interest for this product.	0 GBP	

This illustrates costs in relation to the notional value of the PRIIP.

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MY MONEY OUT EARLY?

The recommended minimum holding period: 5 years.

You should be prepared to stay invested for 5 years. However, you can redeem your investment without penalty at any time during this time, or hold the investment longer. Redemptions are possible any day on which banks in Luxembourg and Zürich are open for business except for 24 December. In exceptional circumstances, your right to request the redemption of your investment may be limited or suspended.

HOW CAN I COMPLAIN?

Complaints about the behaviour of the person who advised you on the product or sold it to you, should be addressed directly to that person. Complaints about the product or the behaviour of the manufacturer of this product should be directed to the following address:

Postal address: FundRock Management Company S.A., 33 Rue de Gasperich, 5826 Hesperange, Luxembourg.

E-mail: FRMC_qualitycare@fundrock.com

https://www.fundrock.com/policies-and-compliance/frd-complaints-handling-policy/

In all cases, the complainant must clearly indicate his/her contact details (name, address, phone number or email address) and provide a brief explanation of the claim.

OTHER RELEVANT INFORMATION

Conversion right: Shareholders are entitled (subject to certain restrictions) to convert all or part of their shares in a class for shares of another class within the same Fund or to switch shares for another of the same or another class within a different Fund of the Company. The investor can obtain information about how to convert in the prospectus of the fund.

Segregation: Under Luxembourg law, the UCITS has segregated liability between its sub-funds (i. e. the UCITS assets will not be used to discharge the liabilities of other Sub-Funds within the umbrella). In addition, the Sub-Fund's assets are held separately from the assets of other sub-funds.

Additional information: Copies of the latest prospectus, annual report, semi-annual report (all available in English), and the latest Net Asset Value per Share, are available free of charge at the registered office of the Management Company, FundRock Management Company S.A. in its offices at H2O building, 33 rue de Gasperich, L-5826 Hesperange, Luxembourg and/or on the following website https://kieger.com/.

Past performance and previous performance scenarios: The cost, performance and risk calculations included in this key information document follow the methodology prescribed by EU rules. Note that the performance scenarios calculated above are derived exclusively from the past performance of the Fund's share price/ suitable benchmark and that past performance is not a guide to future returns. Therefore, your investment may be at risk and you may not get back the returns illustrated. Investors should not base their investment decisions solely upon the scenarios shown.

Any past performance data presented will be for up to 10 calendar years from the date of the launch of a share class. No performance data will be presented for a share class that does not yet have performance data for one complete calendar year as there would be insufficient data to provide a useful indication of past performance to retail investors.

Swiss Disclosure: The state of the origin of the sub fund is Luxumbourg. In Switzerland, the representative is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050, Zurich, whilst the paying agent is Banque Cantonale de Geneve, 17, quai de l'Ile, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi annual reports may be obtained free of charge from the representative. The Swiss ombudsman is Verein Ombudsstelle Finanzdienstleister (OFD), Bleicherweg 10, CH-8002 Zurich.

Previous past performance may be found at: maia.amfinesoft.com/kid_past_performance_bar_chart

Previous performance scenario calculations may be found at: maia.amfinesoft.com/histo_kid_scenario